Case series describes pouchitis after immune checkpoint inhibitors

Two unusual cases of pouchitis occurred in older men receiving therapy for esophageal squamous cell carcinoma and hepatocellular carcinoma.

A case series published Aug. 15 by Annals of Internal Medicine: Clinical Cases detailed two unusual cases of pouchitis after therapy with immune checkpoint inhibitors (ICIs), one in a man in his 70s with esophageal squamous cell carcinoma treated with pembrolizumab and the other in a man in his 60s with hepatocellular carcinoma treated with tremelimumab/durvalumab. The former achieved long-term remission without further flares, while the latter achieved short-term remission. The authors noted that they expect cases of post-ICI pouchitis to increase along with the increasing numbers of patients with inflammatory bowel disease receiving ICI therapy.